All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

42

2023 to 2026

Breakthrough

3

Accelerated

3

Priority review

11

Orphan

4

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202361
202463
2025417
202641

42 approvals

Newest first. Hover a badge for what it means.

  • Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc.Jul 7, 2026
    Original approval · BLA 761486NovelPriority reviewApproval letter

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

  • Utebzi (Tebipenem Pivoxil Hydrobromide) · GlaxosmithklineJun 17, 2026
    Original approval · NDA 215960NovelPriority reviewApproval letter

    To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

  • Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AGMay 29, 2026
    Original approval · NDA 220787NovelPriority reviewApproval letter

    To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

  • Epinephrine (Epinephrine) · Baxter Hlthcare CorpMar 30, 2026
    Original approval · NDA 220626Approval letter
  • Flavalta (Epinephrine Bitartrate, Lidocaine Hydrochloride) · DeprocoMar 19, 2026
    Original approval · NDA 216564Approval letter
  • Oziltus (Denosumab-Mobz) · Amneal Pharms LLCDec 19, 2025
    Original approval · BLA 761457Approval letter
  • Boncresa (Denosumab-Mobz) · Amneal Pharms LLCDec 19, 2025
    Original approval · BLA 761456Approval letter
  • Lerochol (Lerodalcibep-Liga) · Lib Therapeutics, Inc.Dec 12, 2025
    Original approval · BLA 761427NovelApproval letter

    To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise

  • Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025
    Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

  • Conexxence (Denosumab-Bnht) · Fresenius Kabi USA LLCOct 29, 2025
    Original approval · BLA 761398Approval letter
  • Osenvelt (Denosumab-Bmwo) · Celltrion INCOct 29, 2025
    Original approval · BLA 761404Approval letter
  • Denosumab-Dssb (Denosumab-Dssb) · Samsung Bioepis CO LTDOct 29, 2025
    Original approval · BLA 761392Approval letter
  • Aukelso (Denosumab-Kyqq) · Biocon Biologics INCOct 29, 2025
    Original approval · BLA 761436Approval letter
  • Osvyrti (Denosumab-Desu) · Accord Biopharma Inc.Oct 29, 2025
    Original approval · BLA 761424Approval letter
  • Enoby (Denosumab-Qbde) · Hikma Pharmaceuticals USA INCOct 29, 2025
    Original approval · BLA 761439Approval letter
  • Bilprevda (Denosumab-Nxxp) · Shanghai Henlius BiotechOct 29, 2025
    Original approval · BLA 761444Approval letter
  • Enoby (Denosumab-Qbde) · Hikma Pharmaceuticals USA INCSep 26, 2025
    Original approval · BLA 761439Approval letter
  • Aukelso (Denosumab-Kyqq) · Biocon Biologics INCSep 16, 2025
    Original approval · BLA 761436Approval letter
  • Bilprevda (Denosumab-Nxxp) · Shanghai Henlius BiotechAug 29, 2025
    Original approval · BLA 761444Approval letter
  • Vanrafia (Atrasentan Hydrochloride) · NovartisApr 2, 2025
    Original approval · NDA 219208NovelAccelerated approvalApproval letter

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

  • Conexxence (Denosumab-Bnht) · Fresenius Kabi USA LLCMar 25, 2025
    Original approval · BLA 761398Approval letter
  • Blujepa (Gepotidacin Mesylate) · GlaxosmithklineMar 25, 2025
    Original approval · NDA 218230NovelPriority reviewApproval letter

    To treat uncomplicated urinary tract infections

  • Epinephrine (Epinephrine) · Fresenius Kabi USAMar 13, 2025
    Original approval · NDA 215425Approval letter
  • Osenvelt (Denosumab-Bmwo) · Celltrion INCFeb 28, 2025
    Original approval · BLA 761404Approval letter
  • Epinephrine Bitartrate In 0.9% Sodium Chloride (Epinephrine Bitartrate) · Baxter Hlthcare CorpFeb 28, 2025
    Original approval · NDA 218475Approval letter
  • Denosumab-Dssb (Denosumab-Dssb) · Samsung Bioepis CO LTDFeb 13, 2025
    Original approval · BLA 761392Approval letter
  • Unloxcyt (Cosibelimab-Ipdl) · Checkpoint Therapeutics INCDec 13, 2024
    Original approval · BLA 761297NovelApproval letter

    To treat cutaneous squamous cell carcinoma

  • Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
    Original approval · NDA 218808NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat classic congenital adrenal hyperplasia

  • Orlynvah (Probenecid, Sulopenem Etzadroxil) · Iterum TherapOct 25, 2024
    Original approval · NDA 213972NovelPriority reviewApproval letter

    To treat uncomplicated urinary tract infections (uUTI)

  • Neffy (Epinephrine) · Ars Pharms OperationAug 9, 2024
    Original approval · NDA 214697Approval letter
  • Vigafyde (Vigabatrin) · Pyros PharmsJun 17, 2024
    Original approval · NDA 217684OrphanApproval letter
  • Anktiva (Nogapendekin Alfa Inbakicept-Pmln) · Altor Bioscience, LLC, An Indirect Wholly-Owned SuApr 22, 2024
    Original approval · BLA 761336NovelApproval letter

    To treat bladder cancer

  • Vafseo (Vadadustat) · AkebiaMar 27, 2024
    Original approval · NDA 215192NovelApproval letter

    To treat anemia due to chronic kidney disease

  • Jubbonti (Denosumab-Bbdz) · Sandoz INCMar 5, 2024
    Original approval · BLA 761362Approval letter
  • Exblifep (Cefepime Hydrochloride, Enmetazobactam) · Orchid PharmaFeb 22, 2024
    Original approval · NDA 216165NovelPriority reviewApproval letter

    To treat complicated urinary tract infections

  • Defencath (Heparin Sodium, Taurolidine) · CormedixNov 15, 2023
    Original approval · NDA 214520NovelPriority reviewApproval letter

    To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter

  • Rivfloza (Nedosiran Sodium) · NovoSep 29, 2023
    Original approval · NDA 215842NovelBreakthrough therapyOrphanApproval letter

    To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function

  • Posluma (Flotufolastat F-18 Gallium) · Blue EarthMay 25, 2023
    Original approval · NDA 216023NovelApproval letter

    To use with positron emission tomography imaging in certain patients with prostate cancer

  • Elfabrio (Pegunigalsidase Alfa-Iwxj) · Chiesi Farmaceutici SpaMay 9, 2023
    Original approval · BLA 761161NovelPriority reviewApproval letter

    To treat confirmed Fabry disease

  • Adrenalin (Epinephrine) · Ph HealthApr 21, 2023
    Original approval · NDA 215875Approval letter
  • Filspari (Sparsentan) · TravereFeb 17, 2023
    Original approval · NDA 216403NovelAccelerated approvalPriority reviewOrphanApproval letter

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

  • Jesduvroq (Daprodustat) · GlaxosmithklineFeb 1, 2023
    Original approval · NDA 216951NovelApproval letter

    To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.